Navigation Links
Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
Date:3/26/2012

LONDON, March 26, 2012 /PRNewswire/ --

Results presented from new VOYAGER sub-analysis

This release is INTENDED EXCLUSIVELY FOR EUROPEAN media

AstraZeneca today announced the results of a sub-analysis from the VOYAGER individual patient data meta-analysis, which suggests that achieving an LDL-C goal of <70 mg/dL or >50% reduction in LDL-C levels in patients at high risk requires aggressive statin therapy. These goals reflect the latest European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias. Results showed that a significantly greater percentage of patients achieved this goal with CRESTOR™ (rosuvastatin) than with equal or double doses of atorvastatin (Lipitor®) or simvastatin. These findings were presented at the 2012 International Symposium on Atherosclerosis in Sydney, Australia.

This sub-analysis was designed to determine the percentage of high-risk patients treated with rosuvastatin 10-40 mg, atorvastatin 10-80 mg or simvastatin 10-80 mg who achieved this recommended LDL-C goal. Additional findings from the VOYAGER sub-analysis included:

  • As statin dose increased, a higher percentage of patients achieved LDL-C <70 mg/dL or >50% LDL-C reduction.
  • Statistically significant differences (all p<0.001)were observed across a range of statin therapy comparisons, including:
  • Rosuvastatin 10mg vs atorvastatin 10-20mg and simvastatin 10-20mg
  • Rosuvastatin 20mg vs atorvastatin 20-40mg and simvastatin 20-80mg
  • Rosuvastatin 40mg vs atorvastatin 40-80mg and simvastatin 40-80mg

Percentage of high-risk patients achieving LDL-C goal

 

     (Photo: http://www.newscom.com/cgi-bin/prnh/20120326/521032 )

 

"These data reinforce CRESTOR a
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Global commission delivers food security policy recommendations
2. Partnership delivers asthma care to children whose care centers were flooded by Katrina
3. Three-part handoff delivers proteins to membrane surface
4. Cell Press delivers the news
5. Global Rainmakers Delivers World Class Iris Capability for Portoss
6. DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security
7. Homex Delivers Solid Q-1 2010 Revenue Growth of 12.2 Percent
8. BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders
9. ESAs ice mission delivers first data
10. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
11. Toxicologists annual meeting in San Francisco to showcase the latest scientific achievements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... Researchers with Lawrence Berkeley National Laboratory (Berkeley Lab) ... U.S Department of Homeland Security (DHS) in conjunction ... determine how airborne contaminants would spread if released ... is now underway and runs from December 5-11, ...
... Though they remain a leading killer, heart attacks ... diagnosed following initial onset of symptoms. In a study ... , researchers have identified cardiac myosin-binding protein C (cMyBP-C) ... one that may be particularly valuable for mild attacks ...
... Kingdom, December, 2009 Newly published research, by investigators, ... in the journal Stem Cells reported the ... Cell Deficiency" (LSCD) using the patients, own stem cells ... LSCD is a painful, blinding disease that ...
Cached Biology News:Berkeley Lab researchers participate in Homeland Security study of subway airflow 2Potential new heart attack biomarker uncovered 2Successful stem cell therapy for treatment of eye disease 2
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
(Date:3/4/2015)... 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the ... a collaborative research program with Emerald Logic, ... Collective Evolution Technology (FACET), Emerald Logic analyzed ... obtained from each of 798 patients who ... trials ASSERT, SUSTAIN and ASSURE. The objective ...
(Date:3/4/2015)... 04, 2015 Proove Biosciences ... Medicine, is excited to announce the launch of ... Optimize the Management of Pain”. , The continuing ... for the next year. The focus of the ... recognize inadequate pain treatments, integrate appropriate pain management ...
(Date:3/4/2015)... Pa. , March 4, 2015 /PRNewswire/ ... services and technology provider, today announced that ... 10 countries convened at its annual European ... to discuss the use of ... challenges. BioClinica,s eClinical technologies include: the Microsoft ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... (NYSE: DGX ), the nation,s leading provider ... is scheduled to speak,at the Lehman Brothers Eleventh ... at The Loews Miami Beach Hotel, Miami, Florida.,The ... 9:00 a.m.,Eastern Time., The presentation will be ...
... DIEGO, March 14 NuVasive, Inc. (Nasdaq:,NUVA), a medical ... treatments for the spine, announced today,that Kevin O,Boyle, Executive ... at the Lehman Brothers Eleventh Annual Global,Healthcare Conference at ... on,Wednesday, March 19, 2008 at 10:15 a.m. ET., ...
... webcast live and archived on Company,s web site, ... (Nasdaq: MBRK ), a pharmaceutical company focused ... Dr. Edward M. Rudnic, MiddleBrook president and CEO, ... 2008, at 4:45 p.m.,Eastern Time., The presentation ...
Cached Biology Technology:Quest Diagnostics to Speak at Lehman Brothers 11th Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 3MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference 2
... 0-10 psi precision pressure regulator and pressurized ... Faster liquid-switching Steady flow rate ... delivery Can be added to any ... Scientific, any third-party manufacturer, even homemade. Connect to ...
...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity. Novagen&'s enzyme is ... purified to yield the highest activity available, ...
Biology Products: